MENU
+Compare
XRTX
Stock ticker: NASDAQ
AS OF
Jun 13 closing price
Price
$0.89
Change
-$0.00 (-0.00%)
Capitalization
3.41M

XRTX XORTX Therapeutics Forecast, Technical & Fundamental Analysis

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection... Show more

XRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for XRTX with price predictions
Jun 13, 2025

XRTX sees its Stochastic Oscillator recovers from oversold territory

On June 12, 2025, the Stochastic Oscillator for XRTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 73 instances where the indicator left the oversold zone. In of the 73 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XRTX advanced for three days, in of 171 cases, the price rose further within the following month. The odds of a continued upward trend are .

XRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 04, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XRTX as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XRTX turned negative on May 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

XRTX moved below its 50-day moving average on May 22, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XRTX crossed bearishly below the 50-day moving average on May 28, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.223) is normal, around the industry mean (16.950). P/E Ratio (8.000) is within average values for comparable stocks, (59.602). XRTX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.336). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (257.570).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. XRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
XRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

XRTX is expected to report earnings to fall 58.70% to -27 cents per share on May 01

XORTX Therapeutics XRTX Stock Earnings Reports
Q4'23
Est.
$-0.28
Q3'23
Missed
by $0.44
Q2'23
Missed
by $0.64
Q1'23
Missed
by $0.84
Q4'22
Missed
by $2.11
The last earnings report on November 15 showed earnings per share of -67 cents, missing the estimate of -22 cents. With 5.91K shares outstanding, the current market capitalization sits at 3.41M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3710 - 33rd Street NW
Phone
+1 403 607-2621
Employees
12
Web
https://www.xortx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TEOIX9.26-0.10
-1.07%
Transamerica Emerging Markets Eq I
WFINX54.36-0.62
-1.13%
Allspring Index C
VALIX13.31-0.16
-1.19%
Value Line Capital Appreciation Investor
PCAQX81.30-1.02
-1.24%
Principal Capital Appreciation R5
LCAGX15.35-0.23
-1.48%
Lord Abbett International Growth C

XRTX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, XRTX has been loosely correlated with VERV. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if XRTX jumps, then VERV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRTX
1D Price
Change %
XRTX100%
+0.57%
VERV - XRTX
43%
Loosely correlated
-2.53%
BCDA - XRTX
43%
Loosely correlated
-0.91%
SPHDF - XRTX
32%
Poorly correlated
N/A
TRML - XRTX
31%
Poorly correlated
-1.11%
OKYO - XRTX
28%
Poorly correlated
+18.97%
More